Abstract. The role of pancreatic stellate cells (PSCs) has been established in many studies. However, the potential mechanism for the chemoresistance induced by PSCs has not been fully elucidated. In the present study, human pancreatic cancer cell lines were directly or indirectly co-cultured with PSCs. The inhibition rate and IC50 values were assessed to determine the ability of chemoresistance. RT-PCR and western blot analysis were used to evaluate Hes 1 and Jagged 1 expression before and after co-culture with PSCs. To determine the relationship between Hes 1 expression and survival in pancreatic cancer patients, Kaplan-Meier survival analysis was performed. PSCs promoted the expression of Hes 1 in both PANC-1 and BxPC-3 cell lines and induced chemoresistance to gemcitabine. A Notch signaling pathway inhibitor (L1790) and Hes 1 siRNA reversed the chemoresistance induced by PSCs. In 72 resected pancreatic cancer patients, high Hes 1 expression was observed in 34 patients with shorter overall and progression-free survival times. In conclusion, Hes 1 is essential for chemoresistance induced by PSCs and is associated with poor prognosis in pancreatic cancer patients. Therapy targeting the Notch signaling pathway may reverse chemoresistance and improve survival in patients with pancreatic cancer.

Introduction

Despite rapid advances in diagnostic and surgical procedures in the past decade, pancreatic cancer remains the most lethal human malignancy with an extremely low 5-year survival rate (1-3). In the USA, in 2014, it was estimated that there were 46,420 newly diagnosed patients and 39,590 died of this disease (4). A low radical resection rate and insensitive to chemoradiotherapy are the main reasons for the short survival time (1,5-9). Further insights into the mechanisms causing primary or secondary chemoresistance are urgently needed and may reveal new prospects for therapy.

Pancreatic stellate cells (PSCs), first isolated and cultured by Bachem et al and Apte et al in 1998, are the main source of pancreatic fibrosis in patients with chronic pancreatitis and pancreatic cancer (10,11). Many studies have demonstrated that PSCs promote the progression of pancreatic cancer including cell proliferation, migration, invasion and even distant metastasis (12-16). However, the role of PSCs in the chemoresistance of pancreatic cancer has not been fully elucidated.

As an ancient cell signaling system, Notch plays a key role in organ development, cell fate determination and stem cell maintenance (17,18). In adults, alteration of these functions has been associated with many types of malignancies including pancreatic cancer (19). A recent study demonstrated that Notch components, Notch-1, -3 and -4, HES-1 and HEY-1 presented significantly higher nuclear expression in locally advanced and metastatic tumors compared to resectable cancers. In survival analyses, nuclear Notch-3 and HEY-1 expression levels were significantly associated with reduced overall and disease-free survival following curative intent surgery therapy (20).

Targeting the Notch signaling pathway for pancreatic cancer showed promising results in preclinical studies (21-24). The present study revealed that PSCs promoted expression of the Notch component, Hes 1 and chemoresistance to gemcitabine in pancreatic cancer. The Notch signaling pathway inhibitor (L1790) and Hes 1 siRNA reversed the effect of PSCs on chemoresistance. In clinical study, we found that HES 1 expression was associated with shorter overall and disease-free survival in pancreatic cancer patients.

Materials and methods

PSC isolation and cell culture. PSCs were isolated from the normal rat pancreas according to the method established by Apte et al (11) and were maintained in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum (FBS). Two human pancreatic cancer cell lines (PANC-1 and BxPC-3) were cultured in DMEM supplemented with 10% FBS, L-glutamine, and 1% penicillin and streptomycin in a 5% CO2 atmosphere at 37°C unless otherwise indicated.

Co-culture of pancreatic cancer and stellate cells. Pancreatic cancer cells (PANC-1, 1.5x10^5 cells/well and BxPC-3, 1.0x10^5 cells/well) were seeded in 6-well culture plates
(Corning Costar, NY, USA). PSCs (3x10^5 cells/culture insert) were seeded into the culture inserts of 1.0 µm pore size (Corning Costar). On the following day, the culture inserts seeded with PSCs were placed into the 6-well plates containing pancreatic cancer cells, and incubation was continued up to 3 days in DMEM supplemented with 1% FBS, penicillin and streptomycin. Cancer cells after co-culture were collected for chemoresistance analysis.

**Preparation of PSC conditioned medium.** PSC conditioned medium was prepared according to the method as described by Hwang et al (14). Briefly, when PSCs were grown to 70 to 80% confluence in 20-cm² dishes in DMEM/10% FCS, the medium was replaced with serum-free DMEM, and the cells were cultured for 48 h. Then the medium was collected, centrifuged and the supernatant was concentrated with Centricon YM-3 filters (Millipore Corp., Billerica, MA, USA).

**Gemcitabine treatment.** To explore the effect of PSCs on chemoresistance, the cancer cells (co-cultured or not co-cultured with PSCs) were seeded in 6-well (PANC-1, 1.5x10^5 cells/well and BxPC-3, 1.0x10^5 cells/well) or 96-well plates (4x10^3 and 3x10^3 cells/well). Cancer cells cultured with PSCs were incubated with PSC conditional medium. The Cell Counting Kit-8 (CCK-8) was used to calculate the inhibitory rate after incubation with gemcitabine (100 ng/ml; Sigma-Aldrich, St. Louis, MO, USA) for 48 h. To assess the IC_{50} value, different concentrations of gemcitabine (100, 10, 1, 0.1 and 0.01 mg/ml; 1, 0.1, and 0.01 µg/ml; and 1 and 0.1 ng/ml) were added to the co-culture system. GraphPad Prism 6 was used to calculate the IC_{50} value.

**Measurement of apoptosis.** Annexin V-FITC/PI (BD Pharmingen, San Diego, CA, USA) was used for detecting apoptotic cells according to the manufacturer's instructions. Briefly, cells were washed, trypsinized, centrifuged and then resuspended at 1x10^6 cells/ml, and then incubated in binding buffer containing Annexin V-FITC (5 ml) and PI (10 ml) for 15 min in the dark. A BD flow cytometer was used for analysis.

**Hes 1 siRNA transfection.** Pancreatic cancer cells were transfected with Hes 1 siRNA (sense, 5'-AAAGAUAGCUCCGGCAAU-3') using Lipofectamine 2000 according to the manufacturer's instructions.

**RNA isolation, cDNA synthesis and real-time reverse transcription-PCR.** The total RNA from pancreatic cancer cells and siRNA-transfected cancer cells was isolated using TRIsol (Invitrogen Life Technologies, Carlsbad, CA, USA) and purified with the RNeasy Mini kit and RNase-free DNase set (Qiagen, Hilden, Germany) according to the manufacturer's protocols. Total RNA was reverse transcribed using the High Capacity cDNA reverse transcription kit (Applied Biosystems, Foster City, CA, USA) and then mRNA expression was quantified using the TaqMan Gene Expression Assay (Applied Biosystems). The primers used in the PCR reaction for Hes 1 and Jagged-1 were: Hes 1 forward, 5'-GGGCAGAGATAAATGAAAG-3' and reverse, 5'-GCGCGGTACTTCTCCCACA CAC-3' and Jagged-1 forward, 5'-GGGCCAGACTGCAAGA TAAAC-3' and reverse, 5'-CGCGTGCCCTTTGTTGAG-3', respectively.

**Western blot analysis.** To detect changes in the protein levels of Hes 1 (sc-13844) and Jagged 1 (sc-6011) (both from Santa Cruz Biotechnology, Santa Cruz, CA, USA), standard western immunoblotting techniques were used. Cells were lysed in lysis buffer by incubating for 20 min at 4°C. Total proteins were fractionated using SDS-PAGE and transferred onto nitrocellulose membrane for western blotting in routine manner. The blots were then detected using ECL (Illumina, Inc., San Diego, CA, USA).

**Tissue specimens and immunohistochemistry.** Human specimens from 72 patients with pancreatic cancer who underwent R0 resection between January 2004 and 2013 were obtained from the Tissue Bank of the Department of General Surgery, Xuanwu Hospital, Beijing, China. The study was approved by the Ethics Committee of the hospital. Immunohistochemistry on formalin-fixed, paraffin-embedded samples was conducted as previously described. The slides were graded into 3 categories as described earlier (25), from grade 1 to 3, as follows: grade 1, 0-25% staining; grade 2, 26-50% staining; and grade 3, >50% staining.

**Statistical analyses.** Experiments presented in the figures are representative of at least 3 repetitions. Continuous data are presented as mean ± SE and were analyzed by the two-tailed Student's t-test. Categorical variables were analyzed using Chi-square tests. Survival was assessed according to the Kaplan-Meier method; the survival differences were analyzed using the log-rank test. Univariate and multivariate survival analyses were performed using Cox proportional hazard model. Results are reported as relative risk (RR) and 95% confidence intervals (95% CI). SPSS software (version 18.0; SPSS, Inc., Chicago, IL, USA) was used for analysis with a significance level of P<0.05.

**Results**

**PSC isolation.** As described previously, PSCs are mainly located in the interstitium between acini, and negative staining for α-smooth muscle actin (α-SMA) is noted in quiescent PSCs. However, we found that active PSCs were also occasionally visible in the islet in the normal rat pancreas (Fig. 1A). After isolation, Oil-red O staining and vitamin A autofluorescence showed the droplets in the cytoplasm in quiescent PSCs (Fig. 1B and C). Cytoplasmic α-SMA staining was detected in active PSCs which had been cultured for 7 days (Fig. 1D).

**PSC promotes chemoresistance to gemcitabine of pancreatic cancer cells.** Following treatment with gemcitabine (100 ng/ml), the growth inhibition rate was 52.3±12.1% and 65.1±16.8% in the PANC-1 and BxPC-3 cells, respectively. After being cultured with PSC conditioned medium, the inhibition rate significantly decreased to 38.5±11.6% and 51.2±10.9%, respectively (Fig. 2A). The IC_{50} values were also increased significantly in both pancreatic cancer cell lines (Fig. 2B). Flow cytometric analysis revealed that PSCs promoted the anti-apoptosis ability of the cancer cells. The late apoptosis rate of PANC-1 and the early
Figure 1. PSCs isolated from normal rat pancreas. (A) Representative sections of α-SMA immunostaining of the normal rat pancreas. We found that α-SMA positively stained cells were occasionally visible in the islet in normal rat pancreas, which suggests that the PSCs might also exist in the islet and play an important role in maintaining normal structure and function of the islets (magnification, x200). (B) After 24 h in culture, vitamin A autofluorescence at 328 nm revealed blue-green fluorescence and indicated the presence of vitamin A in the cytoplasm (arrow, magnification x200). (C) Oil-red O staining indicated perinuclear lipid droplets after 24 h in culture (magnification x1,000). (D) After seeding for 7 days, positive staining of α-SMA was observed in the cytoplasm (magnification, x400). PSCs, pancreatic stellate cells; α-SMA, α-smooth muscle actin.

Figure 2. PSCs promote chemoresistance to gemcitabine of pancreatic cancer cells. (A) After being cultured with PSC conditioned medium, the inhibition rate for gemcitabine (100 ng/ml) was significantly decreased from 52.3±12.1 and 65.1±16.8% to 38.5±11.6 and 51.2±10.9% in PANC‑1 and BxPC‑3 cells, respectively. (B) The IC50 values were also significantly increased from 78.2±4.8 to 206.5±8.2 ng/ml in the PANC‑1 and from 65.4±6.5 to 189.6±8.1 ng/ml in the BxPC‑3 cells. (C and D) After being co-cultured with PSCs, flow cytometric analysis showed that the late apoptosis rate was significantly decreased from 40.9±2.8 to 31.2±2.6% in the PANC-1 cells. In the BxPC‑3 cells, although the late apoptosis rate did not change significantly before and after co-culture, the early apoptosis rate decreased significantly from 12.8±0.9 to 7.8±1.0%. *P<0.01 vs. the mono-culture; #P<0.05 vs. the mono-culture. PSCs, pancreatic stellate cells.
apoptosis rate of BxPC-3 cells were decreased significantly after co-culture with PSCs (Fig. 2C and D).

**Notch signaling pathway is involved in the chemoresistance induced by PSCs.** After being co-cultured with PSCs for 48 h, the cancer cells were collected for further analysis. RT-PCR analysis revealed that the expression levels of Jagged 1 and Hes 1, members of the Notch signaling pathway were significantly promoted after co-culture with PSCs in both the PANC-1 and BxPC-3 cells. Western blot analysis demonstrated similar results. After being co-cultured with PSCs for 48 h, the cancer cells were collected for further analysis. RT-PCR analysis revealed that the expression levels of Jagged 1 and Hes 1, members of the Notch signaling pathway were significantly promoted after co-culture with PSCs in both the PANC-1 and BxPC-3 cells. Western blot analysis showed similar results. In order to determine the role of the Notch signaling pathway in chemoresistance induced by PSCs, the expression levels of Jagged 1 and Hes 1 were measured using RT-PCR and Western blot analysis. The results showed that the expression levels of Jagged 1 and Hes 1 were significantly increased after co-culture with PSCs. This suggests that the Notch signaling pathway is involved in the chemoresistance induced by PSCs.
by PSCs, L1790 (5 µM, Notch signaling pathway inhibitor) was added to the co-culture system. After introduction of the inhibitor, increased chemoresistance to gemcitabine induced by PSCs was reversed (Fig. 3C). Increased IC50 values for PANC-1 and BxPC-3 cell lines also returned to the levels in the mono-culture (Fig. 3D).

HES 1 is essential for chemoresistance induced by PSCs. To further explore the effect of Hes 1 in the chemoresistance induced by PSCs, we knocked down the expression by siRNA transfection (Fig. 4A and B). After successfully transfection of the Hes 1 siRNA, we found that the effect of PSCs on chemoresistance of PANC-1 and BxPC-3 cells was blocked (Fig. 4C). However, the negative control siRNA did not have any influence on chemoresistance. The effect of PSC on IC50 values for both PANC-1 and BxPC-3 cells was also reversed (Fig. 4D).

**Table I. Demographics of the pancreatic cancer patients who underwent resection (n=72).**

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Data</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>66.5±11.2</td>
</tr>
<tr>
<td>Gender (male/female)</td>
<td>45/27</td>
</tr>
<tr>
<td>Tumor location (head/body/tail)</td>
<td>47/8/17</td>
</tr>
<tr>
<td>Operation (PD/DP)</td>
<td>47/25</td>
</tr>
<tr>
<td>Tumor size (cm)</td>
<td>3.3±1.5</td>
</tr>
<tr>
<td>Differentiation (well/moderate/poor)</td>
<td>7/33/32</td>
</tr>
<tr>
<td>Lymph node metastasis (yes/no)</td>
<td>44/28</td>
</tr>
<tr>
<td>Perineural infiltration (yes/no)</td>
<td>29/43</td>
</tr>
<tr>
<td>Resection margin (-/+</td>
<td>59/13</td>
</tr>
<tr>
<td>AJCC/UICC stage (1A/1B/2A/2B)</td>
<td>6/11/7/48</td>
</tr>
</tbody>
</table>

PD, pancreaticoduodenectomy including classic whipple procedure and whipple+vascular resection; DP, distal pancreatectomy.

**HES 1 expression is associated with poor prognosis in patients with pancreatic cancer.** Seventy-two patients with pancreatic cancer who underwent resection were included in the present study. Patient demographics are shown in Table I. The majority of patients were male (62.5%, 45/72) and had cancer located in the head of the pancreas (65.2%, 47/72). Representative staining of Hes 1 is shown in Fig. 5A-C. Nineteen, 19 and 34 patients had low, moderate and high expression of Hes 1

![A](image1.png)

![B](image2.png)

![C](image3.png)

Figure 5. HES 1 expression is associated with poor prognosis in patients with pancreatic cancer. (A-C) Representative staining of Hes 1 in pancreatic cancer patient tumors (magnification, x200). (A) Grade 1, 0-25% staining; (B) grade 2, 26-50% staining; (C) grade 3, >50% staining. (D) Progression-free survival (PFS) analysis showed that the mean PFS time in grade 1, 2 and 3 patients was 26.6±5.0, 13.7±1.6 and 10.7±0.6 months, respectively. (E) Overall survival (OS) analysis revealed that the mean OS time in grade 1, 2 and 3 patients was 31.8±5.2, 16.3±1.4 and 13.3±0.7 months, respectively. o, observed events; n, number of patients.
and were scored as grade 1, 2 and 3. There was no significant difference among grade 1, 2 and 3 groups (data not shown). The overall survival and progression-free survival time for grade 1 patients were 31.8±5.2 and 26.6±5.0 months, respectively (Fig. 5D and E). Kaplan-Meier analysis showed that high expression of Hes 1 was associated with shorter overall and progression-free survival (Fig. 5D and E). Hes 1 expression was an independent risk factor for poor prognosis in patients with pancreatic cancer. Cox regression analysis revealed that Hes 1 expression (grade 2 and 3) was an independent risk factor for cancer survival (RR, 2.012, 95%; CI, 1.549-10.214; P=0.001) (Table II).

Discussion

The role of gemcitabine in the treatment of pancreatic cancer has been established by a series of excellent trials (6,7,26-30). However, the objective response rate remains unsatisfactory (8,9,31). Primary chemoresistance to single-agent gemcitabine occurred in ~34.5% of metastatic pancreatic cancer patients (8). The addition of cytotoxic and targeted agents to gemcitabine almost invariably provided no significant survival improvement, despite an improvement in response rates in some studies (7,32,33). Stromal cells might play an important role in primary and secondary chemoresistance in cancer patients. As a partner in crime with pancreatic cancer cells, PSCs significantly promote cancer progression in vivo and in vitro studies (14-16,35). Mounting evidence suggests PSCs are both direct and indirect drivers of pancreatic cancer chemoresistance and spread, and thus elucidation of the underlying mechanisms may potentiate current chemotherapy. Our study demonstrated that PSCs promoted the ability of chemoresistance to gemcitabine in both PANC-1 and BxPC-3 cells.

While the cause of chemoresistance is multifactorial, three major processes have been largely clarified: i) reduced drug uptake; ii) increased energy-dependent drug efflux; and iii) alterations in cellular capabilities affecting drug cytotoxicity, such as reduced apoptosis and dysregulated drug metabolism (34). Our study also showed that PSCs reduce late apoptosis in PANC-1 and in BxPC-3 cells which may contribute to chemoresistance. In addition, PSCs stimulated the epithelial-mesenchymal transition (EMT) of cancer cells, which resulted in a more chemoresistant phenotype (35). Cancer stem cells are also involved in the chemoresistance induced by PSCs (36). In an in vitro study and in pancreatic cancer patients, another major determinant of pancreatic cancer chemoresistance was the extensive fibrosis produced by PSCs, which resulted in significant intratumoral hypoxia and a self-perpetuating hypoxia-fibrosis cycle. This impaired drug delivery to cancer cells and stimulated their EMT and genetic instability, yielding a more chemoresistant phenotype (34).

More and more evidence has revealed the fact that the Notch signaling pathway may be a potential target for reversing the chemoresistance of pancreatic cancer. Gungor et al showed that Midkine-Notch-2 interaction activated Notch signaling, induced EMT, upregulated Hes 1 and increased chemoresistance (37). Wang et al demonstrated that in gemcitabine-resistant pancreatic cancer cells, the Notch signaling pathway was overactivated with Notch-2 and Jagged-1 overexpression (38). Kang et al showed that Notch ligand Delta-like 4 (DLL4) induced impaired chemo-drug delivery and enhanced chemoresistance in pancreatic cancer in vivo. Overactivation of the DLL4/Notch pathway enhanced the phenotype of EMT and cancer stem cells, and induced multi-chemoresistance in vitro (39). Our study also demonstrated that PSCs promoted Hes 1 expression and overactivated the Notch signaling pathway. L1790 (Notch signaling pathway inhibitor) and Hes 1 siRNA reversed the chemoresistance induced by PSCs. These results provide molecular evidence showing that Hes 1 is essential for the chemoresistance induced by PSCs.

In view of the Notch signaling pathway in the development of pancreatic cancer, it is not surprising that the Notch expression status is associated with the prognosis of pancreatic cancer patients. We found that Hes 1 high expression is a biomarker for poor prognosis in pancreatic adenocarcinoma.

In conclusion, our results suggest that PSCs induce Hes 1 expression and promote chemoresistance in pancreatic cancer. Hes 1 is an effective prognostic factor and is significantly associated with prognosis of pancreatic cancer patients. Therapy targeting the Notch signaling pathway may reverse chemoresistance and improve survival in patients with advanced pancreatic cancer.

Table II. Results of the univariate and multivariate Cox regression analyses for cancer survival.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Univariate Cox regression</th>
<th>Multivariate Cox regression</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>RR (95% CI)</td>
<td>P-value</td>
</tr>
<tr>
<td>Gender (referent, male)</td>
<td>1.001 (0.321-3.108)</td>
<td>0.115</td>
</tr>
<tr>
<td>Age at diagnosis (referent, &gt;65 years)</td>
<td>2.218 (1.234-12.408)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Primary site of tumor (referent, head)</td>
<td>2.254 (0.993-17.134)</td>
<td>0.478</td>
</tr>
<tr>
<td>T stage (referent, T1)</td>
<td>0.910 (0.219-4.952)</td>
<td>0.126</td>
</tr>
<tr>
<td>N stage (referent, N0)</td>
<td>0.950 (0.275-18.031)</td>
<td>0.271</td>
</tr>
<tr>
<td>Resection margin (referent, positive)</td>
<td>1.998 (0.879-11.258)</td>
<td>0.021</td>
</tr>
<tr>
<td>Gemcitabine therapy (referent, no therapy)</td>
<td>0.749 (0.247-5.867)</td>
<td>0.183</td>
</tr>
<tr>
<td>Hes 1 grade 2 + 3 (referent, grade 1)</td>
<td>2.154 (1.987-11.212)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

RR, relative risk, CI, confidence interval.
References


